Outcome
Case . | Neutrophils more than 5 × 108/L, d . | Reticulocytes more than 1%, d . | Hemoglobin level more than 8.5 g/dL, d . | Platelets more than 50 × 109/L, d . | Acute GVHD grade (organ involvement and stage) . | Chronic GVHD (organ involvement and type) . | Hospitalization, d . | Survival, d* . | Cause of death . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 19 | 25 | 46 | 50 | II (skin 1, liver 0, gut 1) | Limited (skin, quiescent) | 89 | 1558+ | — |
| 2 | 35 | 50 | 224 | 164 | III (skin 3, liver 2, gut 2) | Limited (skin, liver, progressive) | 472 | 307 | Relapse |
| 3 | 26 | 35 | 54 | 49 | 0 | None | 96 | 1312+ | — |
| 4 | 24 | NE | NE | NE | 0 | NE | 169 | 107 | Relapse |
| 5 | 25 | 33 | 88 | 88 | I (skin 1, liver 0, gut 0) | Extensive (skin, lung, progressive) | 243 | 990+ | — |
| 6 | 19 | 28 | 91 | 35 | I (skin 2, liver 0, gut 0) | None | 234 | 928+ | — |
| 7 | 22 | 32 | 46 | 40 | I (skin 1, liver 0, gut 0) | Limited (skin, liver, progressive) | 131 | 828+ | — |
| 8 | 23 | 26 | 46 | 52 | I (skin 1, liver 0, gut 0) | Limited (skin, liver, quiescent) | 172 | 849+ | — |
| 9 | NE | NE | NE | NE | NE | NE | 533 | 368 | Relapse |
| 10 | 26 | 36 | 160 | 85 | I (skin 1, liver 0, gut 0) | None | 240 | 500+ | — |
| 11 | 20 | 26 | 34 | 30 | IV (skin 4, liver 0, gut 2) | Extensive (skin, eye, lung, progressive) | 267 | 437+ | — |
| 12 | 21 | 28 | 34 | 37 | 0 | Limited (skin, liver, de novo) | 124 | 266+ | — |
| 13 | 21 | 28 | 62 | 33 | I (skin 2, liver 0, gut 0) | Extensive (skin, progressive) | 199 | 171+ | — |
Case . | Neutrophils more than 5 × 108/L, d . | Reticulocytes more than 1%, d . | Hemoglobin level more than 8.5 g/dL, d . | Platelets more than 50 × 109/L, d . | Acute GVHD grade (organ involvement and stage) . | Chronic GVHD (organ involvement and type) . | Hospitalization, d . | Survival, d* . | Cause of death . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 19 | 25 | 46 | 50 | II (skin 1, liver 0, gut 1) | Limited (skin, quiescent) | 89 | 1558+ | — |
| 2 | 35 | 50 | 224 | 164 | III (skin 3, liver 2, gut 2) | Limited (skin, liver, progressive) | 472 | 307 | Relapse |
| 3 | 26 | 35 | 54 | 49 | 0 | None | 96 | 1312+ | — |
| 4 | 24 | NE | NE | NE | 0 | NE | 169 | 107 | Relapse |
| 5 | 25 | 33 | 88 | 88 | I (skin 1, liver 0, gut 0) | Extensive (skin, lung, progressive) | 243 | 990+ | — |
| 6 | 19 | 28 | 91 | 35 | I (skin 2, liver 0, gut 0) | None | 234 | 928+ | — |
| 7 | 22 | 32 | 46 | 40 | I (skin 1, liver 0, gut 0) | Limited (skin, liver, progressive) | 131 | 828+ | — |
| 8 | 23 | 26 | 46 | 52 | I (skin 1, liver 0, gut 0) | Limited (skin, liver, quiescent) | 172 | 849+ | — |
| 9 | NE | NE | NE | NE | NE | NE | 533 | 368 | Relapse |
| 10 | 26 | 36 | 160 | 85 | I (skin 1, liver 0, gut 0) | None | 240 | 500+ | — |
| 11 | 20 | 26 | 34 | 30 | IV (skin 4, liver 0, gut 2) | Extensive (skin, eye, lung, progressive) | 267 | 437+ | — |
| 12 | 21 | 28 | 34 | 37 | 0 | Limited (skin, liver, de novo) | 124 | 266+ | — |
| 13 | 21 | 28 | 62 | 33 | I (skin 2, liver 0, gut 0) | Extensive (skin, progressive) | 199 | 171+ | — |
GVHD indicates graft-versus-host disease; NE, not evaluable; —, not applicable.
Ten patients are alive in complete remission at the time of writing. Cases 2, 4, and 9 relapsed on day 266, day 33, and day 53, respectively.